Interest of Functional MRI (Magnetic Resonance Imagery) (in Patients Suffering From Hepatocellular Carcinoma and Treated With Yttrium (ICY)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
For patients who are suffering from hepatocellular carcinoma and are treated with radioembolization, the purpose of this study is to analyse parameters of functional MRIs that are modified early and to detect parameters that vary significantly after treatment.
Modifications of functional MRI parameters [ Time Frame: Before radioembolization and up to 6 months after radioembolization ]
Secondary Outcome Measures :
Correlation between functional MRIs parameters and tumoral response [ Time Frame: Measured 6 months after radioembolization ]
Assessment of alternative morphological response criteria : EASL (European Association for study of the liver) and mRECIST (m response evaluation criteria in solid tumor) criteria. Link with RECIST response. [ Time Frame: 2 and 6 months ]
Change of VEGF (vascular endothelial growth factor) release [ Time Frame: From day 0 to 2 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Early, intermediate, advanced, non metastatic Hepatocellular Carcinoma. Indication for radioembolization validated after pluridisciplinary committee meeting.
Isolated target on initial imagery (invasive hepatocellular carcinoma excluded)
WHO (World Health organization) Performance status: 0, 1 or 2
If cirrhosis, Child A score with total bilirubin less than 30 micromoles per liter
Creatinine clearance more or equal to 30 mL/min
Patient informed and consent signature obtained
Invasive hepatocellular carcinoma without any isolated tumor
Disease needing 2 injections of Therasphere
Thrombosis extending into the porta(thrombosis of one of left or right branch authorized), extra hepatic metastasis
Previous treatment by chemoembolization, radiofrequency less than 3 months before radioembolization
No antiangiogenic concomitant treatment, 15 days before and 15 days after radioembolization, including Sorafenib
Associated disease which could prevent patient from receiving treatment
RMI contre-indication(particle or metal prosthesis, pacemaker, claustrophobia) or contrast product contre-indication (allergy)
Patient already participating in an other therapeutic trial with an experimental drug
Pregnant or childbearing potential women or breastfeeding women
minors, persons deprived of liberty or protected adults (maintenance of justice, guardianship or supervision) Unable to comply with trial medical follow-up for geographical, social or psychological reasons